期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Clinical Course Of Patients with Small Cell Lung Cancer As Second Primary Malignancy
1
作者 王秀问 刘联 王亚伟 《The Chinese-German Journal of Clinical Oncology》 CAS 2005年第5期297-300,325-326,共6页
Objective: To evaluate the clinical course of patients with small cell lung cancer (SCLC) as second primary malignancy. Methods: Among the 355 patients diagnosed with SCLC at Helen and Harry Gray Cancer Center of ... Objective: To evaluate the clinical course of patients with small cell lung cancer (SCLC) as second primary malignancy. Methods: Among the 355 patients diagnosed with SCLC at Helen and Harry Gray Cancer Center of Hartford Hospital Connecticut USA between 1988 and 1998, the records of 48 patients, which had been diagnosed with other malignancies before their diagnosis of SCLC, were retro- spectively reviewed. Results: Forty-eight patients (13.5%) were diagnosed with other malignancies prior to their SCLC among which 43 had documented smoking history and 93% of them (40/43) were current/former smokers. Of the 28-second primary SCLC patients who were treated with standard method, 11 (39.3%) achieved CR. 12 (42.8%) achieved PR, and the RR was 82.1%. The median survival of the 28 treated with standard method was 11.3 months (5.1-77.7 months), while that of the rest 19 untreated patients (1 of 20 was lost to follow-up) was only 2.0 months (0.5 34.0 months). There was no significant difference in the median survival and RR between 165 treated first primary SCLC (13.5 months and 77.6% respectively) and 28 treated secondary primary SCLC (11.3 months and 82.1% respectively) (P〉0.05). The patients who had prostate cancer were older and subjected to less treatments than those with skin cancer, so their survival was shorter than the latter (3.5 months vs. 15 months, P〈0.05). Conclusion: The response and survival of the treated patients with SCLC as a second malignancy showed no difference as compared to the treated ones with SCLC only. Therefore, an active medical treatment is important to relieve symptom and prolong survival of the second primary SCLC patients. 展开更多
关键词 lung neoplasm: cancer small cell lung cancer second primary malignancy
下载PDF
Criminal or bystander: imatinib and second primary malignancy in GIST patients 被引量:3
2
作者 Tatsuo Kanda 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第5期490-492,共3页
Niigata University Hospital is a regional center institution of cancer therapy where many patients with gastrointestinal stromal tumors (GISTs) are visiting to seek the latest treatment.During the time Ⅰ was treati... Niigata University Hospital is a regional center institution of cancer therapy where many patients with gastrointestinal stromal tumors (GISTs) are visiting to seek the latest treatment.During the time Ⅰ was treating GIST patients there with imatinib,a tyrosine kinase inhibitor,a small concern was raised:Ⅰ successively encountered patients who were newly diagnosed as having malignant neoplasms during the course of their treatment.Of the 70 GIST patients who were enrolled in our prospective study of imatinib therapy,seven suffered from second primary malignancies (SPMs).One female GIST patient who suffered from advanced esophageal cancer died of the SPM,whereas the remaining six patients continued with their imatinib therapy and their prognoses were not affected by their SPMs.I reported on the risk of SPMs in GIST patients under imatinib therapy to an international journal of clinical oncology (1).As the patient cohort of our study was so small in number to apply to statistical analysis,our observation was no more than a clinical alert. 展开更多
关键词 GIST imatinib and second primary malignancy in GIST patients Criminal or bystander
下载PDF
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate 被引量:1
3
作者 Jacopo Giuliani Andrea Bonetti 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第5期486-487,共2页
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs deve... Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported (2).The overall frequency of second tumors in different series varied from 4.5% to 33%.The most frequent types of GIST-associated cancers were gastrointestinal carcinomas (47%),lymphoma/leukemia (7%),carcinomas of prostate (9%),breast (7%),kidney (6%),lung (5%),female genital tract (5%),carcinoid tumors (3%),soft tissue and bone sarcomas (3%),malignant melanoma (2%) and seminoma (1%) (1,3-5). 展开更多
关键词 GIST Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
下载PDF
Primitive Neuroectodermal Tumor as the Second Malignant Neoplasm in a Long-Term Survivor Child of Acute Lymphoblastic Leukemia: A Case Report
4
作者 Aoli Zhang Xiaojuan Chen +1 位作者 Zhanqi Li Xiaofan Zhu 《Chinese Medical Sciences Journal》 CAS CSCD 2020年第2期186-190,共5页
Acute lymphoblastic leukemia(ALL)is a common pediatric cancer.The second malignant neoplasms(SMNs)in long-term survivors of pediatric ALL are relatively rare.Herein we report a 10-year-old girl who was diagnosed as pr... Acute lymphoblastic leukemia(ALL)is a common pediatric cancer.The second malignant neoplasms(SMNs)in long-term survivors of pediatric ALL are relatively rare.Herein we report a 10-year-old girl who was diagnosed as primitive neuroectodermal tumor(PNET)5 years after the initial diagnosis of ALL with radiotherapy・free treatment.PNET is an exceedingly rare neoplasm in SMNs of survivors of childhood ALL.It is predisposed to be misdiagnosed and the pathogenesis is unclear.The outcome is poor.Long-term follow-up is necessary for the survival children of ALL. 展开更多
关键词 primitive neuroectodermal tumor second malignant neoplasms CHILDHOOD acute lymphoblastic leukemia
下载PDF
Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany 被引量:16
5
作者 Hans Scherübl Brigitte Streller +8 位作者 Roland Stabenow Hermann Herbst Michael Hopfner Christoph Schwertner Joachim Steinberg Jan Eick Wanda Ring Krishna Tiwari Soren M Zappe 《World Journal of Gastroenterology》 SCIE CAS 2013年第47期9012-9019,共8页
AIM:To study the epidemiologic changes of gastroenteropancreatic neuroendocrine tumors(GEP-NET)in Germany,we analyzed two time periods 1976-1988 and1998-2006.METHODS:We evaluated epidemiological data of GEP-NET from t... AIM:To study the epidemiologic changes of gastroenteropancreatic neuroendocrine tumors(GEP-NET)in Germany,we analyzed two time periods 1976-1988 and1998-2006.METHODS:We evaluated epidemiological data of GEP-NET from the former East German National Cancer Registry(DDR Krebsregister,1976-1988)and its successor,the Joint Cancer Registry(GKR,1998-2006),which was founded after German reunification.Due to a particularly substantial database the epidemiological data from the federal states of Mecklenburg-Western Pomerania,Saxony,Brandenburg and Thuringia,covering a population of more than 10.8 million people,were analyzed.Survival probabilities were calculated using life table analysis.In addition,GEP-NET patients were evaluated for one or more second(non-GEP-NET)primary malignancies.RESULTS:A total of 2821 GEP neuroendocrine neoplasms were identified in the two registries.The overall incidence increased significantly between 1976 and2006 from 0.31(per 100.000 inhabitants per year)to2.27 for men and from 0.57 to 2.38 for women.In the later period studied(2004-2006),the small intestine was the most common site.Neuroendocrine(NE)neoplasms of the small intestine showed the largest absolute increase in incidence,while rectal NE neoplasms exhibited the greatest relative increase.Only the incidence of appendiceal NET in women showed little change between 1976 and 2006.Overall survival of patients varied for sex,tumor site and the two periods studied but improved significantly over time.Interestingly,about 20%of the GEP-NET patients developed one or more second malignancies.Their most common location was the gastrointestinal tract.GEP-NET patients without second malignancies fared better than those with one or more of them.CONCLUSION:The number of detected GEP-NET increased about 5-fold in Germany between 1976 and2006.At the same time,their anatomic distribution changed,and the survival of GEP-NET patients improved significantly.Second malignancies are common and influence the overall survival of GEP-NET patients.Thus,GEP-NET warrant our attention as well as intensive research on their tumorigenesis. 展开更多
关键词 NEUROENDOCRINE Tumor Epidemiology GASTRINOMA INSULINOMA Endoscopy German history REUNIFICATION second malignancy
下载PDF
Low Grade Fibromyxoid Sarcomas and Multiple Myeloma in the Same Patient: One Case Report and Literature Review
6
作者 Chong-mei HUANG Shu-qing LU +3 位作者 Jian-min WANG Xiao-xia HU Li-li WU Jian-min YANG 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第3期210-213,共4页
IntroductionMultiple myeloma (MM) is a neoplastic plasma cell dyscrasia char-acterized by anemia; a monoclonal protein(M-protein) in the serum and/or urine; abnormal bone radiographs and bone pain;hypercal-cemia; ... IntroductionMultiple myeloma (MM) is a neoplastic plasma cell dyscrasia char-acterized by anemia; a monoclonal protein(M-protein) in the serum and/or urine; abnormal bone radiographs and bone pain;hypercal-cemia; and renal insuf.ciency or failure.According to the results of immunoelectrophoresis, patients are separated to Ig type (IgG, IgA, IgD, IgE and IgM); light chain; nonsecretory. 展开更多
关键词 multiple myeloma low grade fibromyxoid sarcomas second malignancy CHEMOTHERAPY alkylating agents radiation
下载PDF
Positron-emission tomography/computed tomography imaging in head and neck oncology:An update
7
作者 Viet D Nguyen Bundhit Tantiwongkosi +1 位作者 Wyatt J Weinheimer Frank R Miller 《World Journal of Otorhinolaryngology》 2016年第2期23-32,共10页
Cancers of the head and neck account for more than half a million cases worldwide annually, with a significant majority diagnosed as squamous cell carcinoma(HNSCC). Imaging studies such as contrast-enhanced computed t... Cancers of the head and neck account for more than half a million cases worldwide annually, with a significant majority diagnosed as squamous cell carcinoma(HNSCC). Imaging studies such as contrast-enhanced computed tomography(CT), magnetic resonance imaging(MRI) and ^(18)F-2-fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography(^(18)F-FDG PET/CT) are widely used to determine the presence and extent of tumors and metastatic disease, both before and after treatment. Advances in PET/CT imaging have allowed it to emerge as a superior imaging modality compared to both CT and MRI, especially in detection of carcinoma of unknown primary, cervical lymph node metastasis, distant metastasis, residual/recurrent cancer and second primary tumors, often leading to alteration in management. PET/CT biomarker may further provide an overall assessment of tumor aggressiveness with prognostic implications. As new developments emerged leading to better understanding and use of PET/CT in head and neck oncology, the aim of this article is to review the roles of PET/CT in both pre- and post-treatment management of HNSCC and PET-derived parameters as prognostic indicators. 展开更多
关键词 Positron emission tomography STAGING Diagnosis Computed tomography Head and neck cancer Management of squamous cell carcinoma Carcinoma of unknown primary second primary malignancy SURVEILLANCE RECURRENCE PROGNOSIS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部